Target intelligence / Profile preview

Pyruvate:ferredoxin oxidoreductase and Ferredoxin system (PFOR/Fd system)

Target
PFOR/Fd system
Molecular classification
Enzyme, Electron transport protein, Oxidoreductase
01

Overview

The Pyruvate:ferredoxin oxidoreductase (PFOR) and Ferredoxin system is the primary metabolic pathway responsible for the reductive activation of nitroimidazole antibiotics, such as metronidazole, in anaerobic bacteria and protozoa (Müller, 1986, PMID: 3521636). These components, often localized in specialized organelles like hydrogenosomes, normally function in anaerobic energy metabolism by transferring low-potential electrons from the oxidation of pyruvate to ferredoxin (Land & Johnson, 1999, PMID: 10506454). In the presence of metronidazole, ferredoxin acts as a high-energy electron donor that reduces the drug's nitro group, creating short-lived, highly reactive nitro radical anions (Leitsch, 2019, PMID: 30617461). These radicals cause catastrophic damage to the pathogen's DNA and proteins, which is the basis of the drug's antimicrobial activity (Samuelson, 1999, PMID: 10430924). Because the expression of these proteins is regulated by environmental iron levels, iron deficiency can lead to the down-regulation of the system, resulting in reduced drug activation and clinical resistance (Upcroft & Upcroft, 2001, PMID: 11226607). This system is therefore a critical therapeutic target and a major factor in the efficacy of treatments for infections like trichomoniasis, giardiasis, and amoebiasis.

Other names
Hydrogenosomal redox chainNitroimidazole activation pathwayPFOR-ferredoxin pathwayIron-regulated nitroreductase system
02

Mechanism of action

Reductive activation of nitroimidazole prodrugs into reactive radical species

03

Biological functions

Anaerobic metabolismElectron transportRedox homeostasisPyruvate oxidation
04

Disease associations

Infection
05

Safety considerations

Development of clinical resistance through down-regulation of componentsCross-resistance among the nitroimidazole classReduced drug efficacy in iron-depleted environments
06

Interacting drugs

Metronidazole

4 more in the full profile.

07

Biomarkers

Ferredoxin expression levelsPyruvate:ferredoxin oxidoreductase activityfd gene mutationspfor gene expressionHydrogenosomal iron concentration

Beyond the preview

Go deeper on Pyruvate:ferredoxin oxidoreductase and Ferredoxin system (PFOR/Fd system).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyruvate:ferredoxin oxidoreductase and Ferredoxin system (PFOR/Fd system).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call